Completed PHASE1 INTERVENTIONAL 12-arm NCT02432235

Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma

A Phase 1 Adaptive Dose-Escalation Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of ADCT-301 in Patients With Relapsed or Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma

Sponsor: ADC Therapeutics S.A.

Conditions Hodgkin Lymphoma Non-Hodgkin Lymphoma

Interventions Camidanlumab tesirine

Updated 20 times since 2017 Last updated: Jul 12, 2021 Started: Oct 5, 2015 Primary completion: Oct 24, 2019 Completion: Oct 24, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Hodgkin Lymphoma and Non-Hodgkin Lymphoma and is currently completed. ADC Therapeutics S.A. leads this study, which shows 20 recorded versions since 2015 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

20 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Sep 2021 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — Sep 2021 [monthly]

Completed PHASE1
Apr 2020 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 15 earlier versions

Mar 2020 — Apr 2020 [monthly]

Completed PHASE1
Jan 2020 — Mar 2020 [monthly]

Completed PHASE1
Dec 2019 — Jan 2020 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
Aug 2019 — Dec 2019 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
Mar 2019 — Aug 2019 [monthly]

Recruiting PHASE1
Jan 2019 — Mar 2019 [monthly]

Recruiting PHASE1
Dec 2018 — Jan 2019 [monthly]

Recruiting PHASE1
Nov 2018 — Dec 2018 [monthly]

Recruiting PHASE1
Jun 2018 — Nov 2018 [monthly]

Recruiting PHASE1
Feb 2018 — Jun 2018 [monthly]

Recruiting PHASE1
Nov 2017 — Feb 2018 [monthly]

Recruiting PHASE1
Oct 2017 — Nov 2017 [monthly]

Recruiting PHASE1
Jun 2017 — Oct 2017 [monthly]

Recruiting PHASE1
Feb 2017 — Jun 2017 [monthly]

Recruiting PHASE1
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE1

First recorded

Oct 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

ADC Therapeutics S.A.

Data source: ADC Therapeutics S.A.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Cleveland, United States , Duarte, United States , Fairfax, United States , Houston, United States , London, United Kingdom , Manchester, United Kingdom , Milwaukee, United States , New York, United States , Newcastle upon Tyne, United Kingdom , Oxford, United Kingdom and 2 more locations